Navigation Links
International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping in Breast Cancer Treatment
Date:8/10/2011

IRVINE, California and AMSTERDAM, August 10, 2011 /PRNewswire/ --

Agendia, a commercial-stage molecular cancer diagnostics company, today announced that the 12th St. Gallen International Breast Cancer Conference (2011) Expert Panel's recommendations highlight the value of molecular subtyping - classifying patients by the particular biological subtype of their tumor - in guiding treatment decisions for breast cancer patients. According to the panel, "it is no longer tenable to consider breast cancer as a single disease" and clinicians "should consider cases within the various distinct subtypes in order to properly assess the relevant evidence and arrive at appropriate therapeutic advice." The panel's updated guidelines, which are released on a semiannual basis, appear in the August 2011 issue of Annals of Oncology in an article titled "Expert Consensus on the Primary Therapy of Early Breast Cancer 2011" by Goldhirsch, et al (Annals of Oncology 22: 1736-1747, 2011).

The panel's recommendations support the clinical value of Agendia's BluePrint assay, which, in combination with the company's FDA-cleared MammaPrint® recurrence test, can accurately classify all patients as Basal, Luminal-A, Luminal-B, or ERBB2 (HER2) and help determine appropriate treatment. Both clinically available, MammaPrint and BluePrint are two components of Agendia's Symphony™ suite of breast cancer treatment products, a comprehensive collection of genetic assays that help address complex treatment decisions for any type and stage of breast cancer.

The panel also recognized that MammaPrint provided such accurate prognoses that patients and physicians may decide that chemotherapy is not required. MammaPrint identifies patients' risk of metastasis, placing them into one of just two groups, high risk and low risk. Women in the low risk group are able to be treated effectively and safely without undergoing chemotherapy and its side effects.

"These recommendations reinforce what Agendia has known for some time - that molecular subtyping is an invaluable component of the treatment decision process in breast cancer," said Dr. Bernhard Sixt, CEO and Cofounder of Agendia. "Along with MammaPrint's proven prognostic ability to classify breast cancer patients according to recurrence risk, BluePrint and Symphony's other tests offer a very powerful set of tools to help physicians eliminate uncertainty and make better treatment decisions."

About Agendia:

Agendia is a leading global commercial molecular diagnostic company that develops and markets genomic-based diagnostic products that improve the quality of life for cancer patients and simplifies complex treatment decisions for their physicians. Agendia's Symphony™ suite of breast cancer products is based on the analysis of hundreds of genes in a patient's breast and provides unprecedented biological insight to address complex treatment decisions. Symphony™ includes MammaPrint®, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint®, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, a therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo or hormonal therapy, and which patients do not require these treatments and can instead be treated with other less arduous and costly methods.

In addition to the Symphony™ suite of tests, Agendia has a rich pipeline of genomic products in development based on its world-class genomic platform. The company also collaborates with pharmaceutical companies to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.

Agendia was founded in 2003 as a spin-off of the Netherlands Cancer Institute and is based in Irvine, California, United States, and Amsterdam, the Netherlands. For more information, please visit http://www.agendia.com.


'/>"/>
SOURCE Agendia B.V.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results
2. Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2011
3. Millennium Surgical Provides Services and Support to CURE Internationals Zambian Surgical Program
4. HUYA Bioscience International and Shanghai Jiao Tong University Kings Lab Form Alliance
5. Masimo Introduces Pronto-7™ Internationally and Lifts Voluntary Recall
6. HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010
7. VWR International, LLC to Acquire LabPartner (Shanghai) Co., Ltd.
8. Lightwave Logic Addresses the Bio-Medical Diagnostic Market through an Agreement with FiberLogix International Ltd.
9. FedEx Donates $5 Million and MD-10-30 Aircraft to ORBIS International
10. FDA, International Counterparts Report Progress on Drug Inspection Collaboration
11. Chindex International, Inc. to Report Financial Results for the Second Quarter and First Half of 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... "The World Market for Companion Diagnostic Tests" report to ... World Market for Companion Diagnostics The World ... diagnostic and personalized medicine diagnostics. Market analysis in the report ... Diagnostics Test Market (In Vitro Diagnostic Kits) by Region (N. ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
Breaking Medicine News(10 mins):